GLP-1 Mounjaro May Lower Heart Attack Risk
“Tirzepatide does not currently have FDA approval for cardiac risk reduction, and thus, coverage and usage are limited to patients with type 2 diabetes, obesity, and obstructive sleep apnea,” said David Rhee, MD, board certified cardiologist with Manhattan Cardiology in NYC, who wasn’t involved in the study. Mounjaro is currently only approved for the treatment […]
